Sanofi and Innate Pharma expand collaboration for Natural Killer cell therapeutics in oncology
Innate Pharma presents data from ongoing Phase 2 TELLOMAK trial demonstrating clinical activity of lacutamab in advanced Sézary syndrome at ASH 2022
Innate Pharma Reports Third Quarter Financial Results
Innate Pharma to present results from a preliminary analysis of the TELLOMAK Phase 2 trial in patients with advanced Sezary syndrome and ANKET platform at ASH 2022
Innate Pharma presents data from ongoing Phase 2 TELLOMAK trial demonstrating clinical activity of lacutamab in advanced mycosis fungoides
Innate Pharma reports first half 2022 financial results and business update
Innate Pharma to present lacutamab PTCL Phase 1b design and ANKET platform at ESMO 2022
Innate Pharma provides update on AstraZeneca-sponsored Interlink-1 Phase 3 study
Second Innate Pharma NK Cell Engager Selected by Sanofi as drug candidate for development
Innate Pharma reports First Quarter 2022 financial results and business update
